UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For
the quarterly period ended
or
For the transition period from ______________ to ______________
Commission
File No.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
|
|
| (Address of principal executive office) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
|
|
The
|
||
| Warrants to purchase Common Stock | SQLLW | The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
|
|
☒ | Smaller reporting company |
|
| Emerging growth company |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November
8,
2022, there were
TABLE OF CONTENTS
i
EXPLANATORY NOTE
In this Quarterly Report on Form 10-Q, and unless the context otherwise requires, the “Company,” “we,” “us,” and “our” refer to SeqLL Inc. and its wholly owned subsidiary SeqLL, LLC, taken as a whole.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in this report and in other documents which we file with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to:
| ● | the success, cost and timing of our product development activities, including statements regarding the timing of initiation and completion of our research and development programs; |
| ● | developments regarding next generation sequencing technologies; |
| ● | our expectations regarding the market size and growth potential for our business; |
| ● | our ability to generate sustained revenue or achieve profitability; |
| ● | the potential for our identified research priorities to advance our technology; |
| ● | the pricing and expected gross margin for our products; |
| ● | the other factors discussed in the “Risk Factors” section and elsewhere in this report. |
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the filing date of this report.
ii
PART I. FINANCIAL INFORMATION
Item 1: Financial Statements
SeqLL Inc.
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | (Unaudited) | |||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ |
|
$ |
|
||||
| Marketable securities |
|
|
||||||
|
Accounts receivable, net of allowance for doubtful accounts of $
|
|
|
||||||
| Other receivables |
|
|
||||||
| Inventory |
|
|
||||||
| Prepaid expenses |
|
|
||||||
| Total current assets |
|
|
||||||
| Other assets | ||||||||
| Property and equipment, net |
|
|
||||||
| Operating lease right-of-use asset |
|
|||||||
| Other assets |
|
|
||||||
| Total assets | $ |
|
$ |
|
||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ |
|
$ |
|
||||
| Accrued expenses |
|
|
||||||
| Non-convertible promissory notes - current | - |
|
||||||
| Current portion of operating lease liability |
|
|||||||
| Total current liabilities |
|
|
||||||
| Non-current liabilities | ||||||||
| Operating lease liability, less current portion |
|
|||||||
| Non-convertible promissory notes - long-term |
|
- | ||||||
| Total liabilities |
|
|
||||||
| Commitments and contingencies (Note 11) | ||||||||
| Stockholders’ equity | ||||||||
|
Preferred stock, $
|
||||||||
|
Common stock, $
|
|
|
||||||
| Additional paid-in capital |
|
|
||||||
| Accumulated deficit |
(
|
) |
(
|
) | ||||
| Total stockholders’ equity |
|
|
||||||
| Total liabilities and stockholders’ equity | $ |
|
$ |
|
||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1
SeqLL Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
|
Three months ended
September 30, |
Nine months ended
September 30, |
|||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | ||||||||||||||||
| Sales | $ | - | $ |
|
$ |
|
$ |
|
||||||||
| Grant revenue | - |
|
|
|
||||||||||||
| Total revenue | - |
|
|
|
||||||||||||
| Cost of sales | - |
|
|
|
||||||||||||
| Gross profit | - |
|
|
|
||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development |
|
|
|
|
||||||||||||
| General and administrative |
|
|
|
|
||||||||||||
| Total operating expenses |
|
|
|
|
||||||||||||
| Operating loss |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| Other (income) and expenses | ||||||||||||||||
| Unrealized loss (gain) on marketable securities |
|
(
|
) | |||||||||||||
| Realized loss on marketable securities |
|
|||||||||||||||
| Interest and other income |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| Change in fair value of convertible notes |
|
|
||||||||||||||
| Loss on extinguishment of convertible notes |
|
|||||||||||||||
| Interest expense |
|
|
|
|
||||||||||||
| Net loss | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | ||||
| $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | |||||
|
|
|
|
|
|||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
SeqLL Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
(Unaudited)
| Preferred Stock | Common Stock | Additional Paid-In | Accumulated | Total Stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||||||||
| Balance as of December 31, 2021 | $ |
|
$ |
|
$ |
|
$ |
(
|
) | $ |
|
|||||||||||||||||
| Stock-based compensation expense | - | - |
|
|
||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||
| Balance as of March 31, 2022 |
|
|
|
(
|
) |
|
||||||||||||||||||||||
| Stock-based compensation expense | - | - |
|
|
||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||
| Balance as of June 30, 2022 |
|
|
|
(
|
) |
|
||||||||||||||||||||||
| Stock-based compensation expense | - | - |
|
|
||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||
| Balance as of September 30, 2022 | $ |
|
$ |
|
$ |
|
$ |
(
|
) | $ |
|
|||||||||||||||||
| Preferred Stock | Common Stock | Additional Paid-In | Accumulated | Total Stockholders’ | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity (Deficit) | ||||||||||||||||||||||
| Balance as of December 31, 2020 |
|
$ |
|
|
$ |
|
$ |
|
$ |
(
|
) |
(
|
) | |||||||||||||||
| Stock-based compensation expense | - | - |
|
|
||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||
| Balance as of March 31, 2021 |
|
|
|
|
|
(
|
) |
(
|
) | |||||||||||||||||||
| Stock-based compensation expense | - | - |
|
|
||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||
| Balance as of June 30, 2021 |
|
|
|
|
|
(
|
) |
(
|
) | |||||||||||||||||||
| Stock-based compensation expense | - | - |
|
|
||||||||||||||||||||||||
| Conversion of preferred stock into common stock |
(
|
) |
(
|
) |
|
|
|
|||||||||||||||||||||
| Conversion of convertible notes into common stock | - |
|
|
|
|
|||||||||||||||||||||||
|
Issuance of Units and warrants to underwriters in initial public offering, net of issuance costs of $
|
- |
|
|
|
|
|||||||||||||||||||||||
|
Issuance of common stock to underwriters in initial public offering, net of issuance costs of $
|
- |
|
|
|
|
|||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||
| Balance as of September 30, 2021 | $ |
|
$ |
|
$ |
|
$ |
(
|
) | $ |
|
|||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
SeqLL Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
|
Nine months ended
September 30, |
||||||||
| 2022 | 2021 | |||||||
| Cash Flows from Operating Activities | ||||||||
| Net loss | $ |
(
|
) | $ |
(
|
) | ||
| Adjustment to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation |
|
|
||||||
| Unrealized gain on marketable securities |
(
|
) | ||||||
| Realized loss on marketable securities |
|
- | ||||||
| Loss on extinguishment of notes |
|
|||||||
| Stock-based compensation |
|
|
||||||
| Change in fair value of convertible notes |
|
|||||||
| Non-cash lease expense |
|
|||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net |
|
(
|
) | |||||
| Other receivables |
(
|
) |
|
|||||
| Prepaid expenses |
(
|
) |
(
|
) | ||||
| Inventory |
(
|
) |
(
|
) | ||||
| Other assets |
(
|
) | ||||||
| Accounts payable |
(
|
) |
(
|
) | ||||
| Accrued expenses |
(
|
) |
|
|||||
| Net cash used in operating activities |
(
|
) |
(
|
) | ||||
| Cash Flows from Investing Activities | ||||||||
| Purchases of lab equipment |
(
|
) |
(
|
) | ||||
| Purchases of marketable securities |
(
|
) | ||||||
| Sales of marketable securities |
|
|||||||
| Net cash provided by (used in) investing activities |
|
(
|
) | |||||
| Cash Flows from Financing Activities | ||||||||
| Proceeds from issuance of units, gross |
|
|||||||
| Proceeds from issuance of common stock to underwriters, gross |
|
|||||||
| Payment for issuance costs of units and common stock |
(
|
) | ||||||
| Proceeds from issuance of convertible notes |
|
|||||||
| Settlement of convertible notes |
(
|
) | ||||||
| Proceeds from loan payable – related party |
|
|||||||
| Payment of loan payable – related party |
(
|
) | ||||||
| Net cash provided by financing activities |
|
|||||||
| Net increase in cash and cash equivalents |
|
|
||||||
| Cash and cash equivalents, beginning of period |
|
|||||||
| Cash and cash equivalents, end of period | $ |
|
$ |
|
||||
| Non-cash investing activities | ||||||||
| Right-of-use asset acquired through operating lease | $ |
|
$ | |||||
| Leasehold improvements financed through tenant improvement allowance | $ |
|
$ | |||||
| Conversion of notes at initial public offering into common stock | $ | $ |
|
|||||
| Issuance costs in accounts payable | $ | $ |
|
|||||
| Fair value of warrants for common stock issued to underwriters | $ | $ |
|
|||||
| Conversion of preferred stock par value to common stock and additional paid-in capital | $ | $ |
|
|||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
SeqLL Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1 – Nature of Operations and Basis of Presentation
SeqLL
Inc. was incorporated as a Delaware corporation on April 3, 2014. On April 8, 2014, SeqLL Inc. acquired a
Initial Public Offering
On
August 31, 2021, the Company completed its initial public offering (“IPO”) whereby it sold
Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 45-day option to purchase up to
Notice from the Nasdaq Stock Market
On
June 21, 2022, SeqLL received notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price
for its common stock has fallen below $
The
notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock or its warrants to
purchase common stock under the symbols “SQL” and “SQLLW,” respectively.
If the Company does not regain compliance by December 18, 2022, the Company may be eligible for an additional grace period. To qualify, the Company would be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period. If the Company meets these requirements, the Nasdaq staff will grant an additional 180 calendar days for the Company to regain compliance with the minimum bid price requirement. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on The Nasdaq Capital Market until the completion of the appeal process.
5
Risks and Uncertainties
The Company is subject to a number of risks similar to other companies in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.
Results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond the Company’s control. The Company’s business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact the Company’s business.
Basis of Presentation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, SeqLL, LLC. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2022 and its results of operations for the three- and nine-months ended September 30, 2022 and 2021, and changes in shareholders’ equity and cash flows for the periods presented. The results disclosed in the condensed consolidated statements of operations for the three- and nine-months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 filed with the Securities and Exchange Commission.
Note 2 – Significant Accounting Policies
During the nine-month period ended September 30, 2022, there were no changes to the significant accounting policies in relation to what was described in the Annual Report on Form 10-K for the year ended December 31, 2021, other than the items noted in the Recently Adopted Accounting Standards section below.
Use of Estimates
The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include but are not limited to stock-based compensation expense and research and development accruals. Actual results could differ from those estimates and changes in estimates may occur.
Investments in marketable securities
The Company accounts for its investments in debt securities in accordance with Accounting Standards Codification (“ASC”) 320, Investments — Debt Securities (“ASC 320”). Debt securities, which are comprised of investments in U.S. Treasury Securities, are measured at fair value, based on quoted market prices. As the Company has classified its investments in debt securities as available-for-sale, the Company recognizes all unrealized gains and losses in other comprehensive income, net of tax, and recognizes all realized gains and losses in the Company’s statement of operations.
The Company accounts for its investments in equity securities in accordance with ASC 321, Investments — Equity Securities (“ASC 321”). Equity securities, which are comprised of investments in mutual funds shares, are measured at fair value, based on quoted market prices, with all gains and losses reported in the Company’s statement of operations.
6
The Company may sell its debt or equity securities in response to changes in interest rates, risk/reward characteristics, liquidity needs or other factors.
Inventory
Inventory consists of finished goods, work-in-process and raw materials and is valued at the lower of cost or net realizable value, determined by the first-in, first-out (“FIFO”) method. As the Company manufactures the finished goods and work-in-process materials, overhead costs are included in inventory. The Company evaluates the carrying cost of finished goods, work-in-process and raw materials items. To the extent that such costs exceed future demand estimates and /or exhibit historical turnover at rates less than current inventory levels, the Company reduces the carrying value of the applicable inventories. Inventory consisted of the following:
| September 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Raw materials | $ |
|
$ |
|
||||
| Work in process |
|
|
||||||
| Total inventory | $ |
|
$ |
|
||||
Stock-based Compensation
The Company’s share-based compensation program grant awards include stock options and restricted stock awards to employees, directors and consultants. The fair value of stock option grants is estimated as of the date of the grant using the Black-Scholes option pricing model. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant. The fair value of the stock-based awards is then expensed over the requisite service period, generally the vesting period, for each award.
The
Company’s expected stock price volatility assumption is based on the volatility of comparable public companies. The expected term
of a stock option granted to employees and directors (including non-employee directors) is based on the average of the contractual term
(generally
The Company has periodically granted stock options and restricted stock awards to consultants for services, pursuant to the Company’s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would be cancelled. For awards granted to consultants and non-employees, compensation expense is recognized over the vesting period of the awards, which is generally the period services are rendered by such consultants and non-employees.
The assumptions used in determining the fair value of share-based awards granted during the nine-months ended September 30, 2022 are as follows:
|
September 30,
2022 |
||||
| Risk-free interest rate |
|
% | ||
| Expected option life |
|
|||
| Expected dividend yield |
|
% | ||
| Expected stock price volatility |
|
% | ||
7
Segments
The Company operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies.
Leases
In the first quarter of 2022, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) . The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company recognizes right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company’s incremental borrowing rate and amortizing over the remaining terms of the leases. The Company accounts for the leases of less than 12 months as short-term leases. See the Recently Adopted Accounting Standards below for additional information related to the adoption of this accounting standard.
Net Loss per Share
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.
The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive:
| September 30, | ||||||||
| 2022 | 2021 | |||||||
| Stock options |
|
|
||||||
| Warrants for common stock |
|
|
||||||
Recently Adopted Accounting Standards
In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard on January 1, 2022, which had no material impact to the Company’s condensed consolidated financial statements.
In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”) which establishes new accounting and disclosure requirements for leases. ASU No. 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. The Company adopted ASU 2016-02 in the first quarter of 2022 using the effective date approach to recognize and measure leases as of the adoption date. The Company has elected to utilize the available practical expedient to not separate lease components from non-lease components as well as the package of practical expedients that allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. At the date of adoption on January 1, 2022, this guidance had no impact to the Company’s condensed consolidated financial statements.
8
Recently Issued Accounting Standards
The Company does not believe that other recently issued but not yet effective accounting pronouncements are expected to have a material effect on the Company’s condensed consolidated financial statements.
Note 3 – Accrued Expenses
Accrued expenses consisted of the following:
| September 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Accrued interest | $ |
|
$ |
|
||||
| Other |
|
|
||||||
| $ |
|
$ |
|
|||||
Note 4 – Fair Value Measurements
The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and requires disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
| Level 1: | Observable inputs such as quoted prices in active markets. |
| Level 2: | Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. |
| Level 3: | Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. |
As of September
30, 2022, the Company had $
As of December
31, 2021, the Company had $
There were no liabilities measured at fair value at September 30, 2022 or December 31, 2021.
9
The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis for the nine-month period ended September 30, 2021.
|
Convertible
Notes |
||||
| Balance at December 31, 2020 | $ | |||
| Issuance of Amended Notes |
|
|||
| Change in fair value of convertible notes |
|
|||
| Fair value of convertible notes at IPO date |
(
|
) | ||
| Balance at September 30, 2021 | $ | |||
At the IPO date, the Amended Notes (as defined
in Note 7) were converted into
There were no assets or liabilities measured at fair value on a non-recurring basis during the three- and nine- months ended September 30, 2022 or 2021.
The carrying values of financial instruments such as accounts receivable, net, other receivables, accounts payable, and accrued expenses approximated fair value as of September 30, 2022 and December 31, 2021 due to their short-term maturities.
The carrying value of the Company’s Non-Convertible Promissory Note approximated its fair value as of September 30, 2022 and December 31, 2021.
Note 5 – Stock Option Plan
The
Company’s 2014 Equity Incentive Plan (the “2014 Plan”) permits the grant of options for its common stock and shares
of common stock to its employees, board members and consultants for up to
As
of September 30, 2022, there were
The stock option activity for the period ended September 30, 2022 is as follows:
|
Number of
Options |
Weighted-
Average Exercise Price per Share |
Weighted
Average Remaining Contractual Term (in Years) |
||||||||||
| Outstanding as of December 31, 2021 |
|
$ |
|
|
||||||||
| Granted |
|
$ |
|
|||||||||
| Outstanding of September 30, 2022 |
|
$ |
|
|
||||||||
| Exercisable at September 30, 2022 |
|
$ |
|
|
||||||||
10
During the three months ended September 30, 2022 and 2021, the Company
recorded $
During the nine months ended September 30, 2022 and 2021, the Company
recorded $
As
of September 30, 2022, there was approximately $
Note 6 – Related Party Transactions
At September 30, 2022 and December 31, 2021, the Company had the following outstanding payables to its shareholders for past services, which are included within the Company’s accounts payable above:
|
September 30, 2022 |
December 31,
2021 |
|||||||
| Genomic Diagnostic Technologies | $ | $ |
|
|||||
| St. Laurent Institute |
|
|
||||||
| St. Laurent Realty, Inc. |
|
|
||||||
| Total related party payables | $ |
|
$ |
|
||||
The above entities are affiliated with (1) William C. St. Laurent, a former member of the Company’s board of directors, (2) relatives of Mr. St. Laurent or (3) entities controlled by the St. Laurent family, who are controlling shareholders of the Company. St. Laurent Realty, Inc. and Genomic Diagnostic Technologies assisted the Company by previously providing corporate accounting support; St. Laurent Institute, a non-for-profit company, provided bioinformatics specialist support for certain sequencing services.
Note 7 – Notes Payable
The
Company entered into a series of convertible promissory notes (the “Convertible Notes”) through April 8, 2019, with certain
preferred stockholders amounting to $
From
April 29, 2019, to April 29, 2020, the Company entered into a series of non-convertible promissory notes (the “Promissory Notes”)
with a certain preferred stockholder amounting to $
In
November and December 2020, the Company issued senior secured convertible promissory notes to a third-party investor amounting to $
11
On
December 31, 2020, the Company issued a non-convertible promissory note to St. Laurent Investments LLC amounting to $
From
January to March 2021, the Company issued senior secured convertible promissory notes to investors for total proceeds of $
On
February 3, 2021, the preferred stockholder and the holder of $
In
March 2021, the Company entered into a series of agreements with the noteholders to automatically convert $
On
April 29, 2021, the Company entered into an agreement with a noteholder to automatically convert an additional $
At
the IPO date, the Amended Notes automatically converted based on their original terms into
The
Company recognized $
In
October 2021, the Company entered into an agreement with St. Laurent Investments LLC to reduce the interest on $
In
October 2021, the Company repaid $
In
connection with all the Convertible Notes and Promissory Notes issued during 2021 and 2020, the Company issued warrants to noteholders
to purchase the total of
In
June 2022, the Company entered into an agreement with St. Laurent Investments LLC to extend the maturity date of the $
For
the three months ended September 30, 2022 and 2021, interest expense was $
For
the nine months ended September 30, 2022 and 2021, interest expense was $
12
Note 8 – Common Stock Warrants
The following table summarizes information with regard to outstanding warrants to purchase the Company’s common stock as of September 30, 2022:
| Issuance Date |
Number of
Shares Issuable Upon Exercise of Outstanding Warrants |
Exercise
Price |
Expiration Date | |||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
|
$ |
|
|
||||||
|
|
||||||||||
During the nine-month period ended September 30,
2022, warrants to purchase
13
Note 9 – Preferred Stock
The Company had outstanding preferred stock as of December 31, 2020:
|
Shares
authorized |
Shares
issued |
Issuance price
per share |
||||||||||
| Series A-1 Convertible Preferred Stock |
|
$ |
|
|||||||||
| Series A-2 Convertible Preferred Stock |
|
$ |
|
|||||||||
| Series A Preferred stock |
|
|
||||||||||
The Series
A-1 Preferred Stock (“Series A-1”) and Series A-2 Preferred Stock (“Series A-2”) collectively the Preferred Stock”,
could be converted at any time at the election of the holder into common stock at an initial conversion price determined by dividing the
Series A-1 original issue price of $
The Preferred Stock was subject to automatic conversion upon (i) the closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in which the Company raised gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding shares of Preferred Stock voting together as a single class.
In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock, upon the consent of the holders of a majority of the Preferred Stock, automatically converted into 3,130,622 shares of common stock.
Note 10 – Marketable Securities
In January 2022, the Company sold all of its marketable
securities in its possession at December 31, 2021 with the original cost $
In September 2022, the Company purchased marketable
securities at a cost of $
Note 11 – Commitments and Contingencies
The Company’s office space lease in Woburn,
Massachusetts (the “Woburn Lease”) for the Company’s corporate headquarters was on a month-to-month basis since November
2020 and was terminated in February 2022. The rent expense for this lease was $
On February 2, 2022, the Company entered into a
lease agreement for approximately
14
The Billerica Lease is
classified as an operating lease. At the inception date of the Billerica Lease, the Company recorded a right-of-use asset of $
In August 2022, the Company
received the tenant improvement allowance from the landlord, which totalled approximately $
The Company recorded expense
related to the Billerica Lease in the amount of $
During the three and nine
months ended September 30, 2022, the Company made cash payments of $
The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the condensed consolidated balance sheet as of September 30, 2022:
| 2022 (remaining) | $ |
|
||
| 2023 |
|
|||
| 2024 |
|
|||
| 2025 |
|
|||
| Thereafter |
|
|||
| Total undiscounted lease liabilities | $ |
|
||
| Less effects of discounting |
(
|
) | ||
| Total lease liabilities | $ |
|
||
| Reported as of September 30, 2022: | ||||
| Current portion of operating lease liability | $ |
|
||
| Operating lease liability, less current portion |
|
|||
| Total lease liabilities | $ |
|
Note 12 — Paycheck Protection Program
On May 5, 2021, the Company applied for and
received a loan for $
The loan had a term of
Some or all of the loan could be forgiven if at
least
The Company elected to account for the PPP loan as an in-substance government grant by applying the guidance in International Accounting Standards 20 by analogy based on the assessment that it is probable that it will meet both (a) the eligibility criteria for a PPP loan, and (b) the loan forgiveness criteria for all or substantially all of the PPP loan. Under this guidance, the Company recorded the loan proceeds in other income in the condensed consolidated statement of operations for the three and nine months ended September 30, 2021.
Note 13 — Subsequent Events
On October 13, 2022, the Company’s PPP Loan
dated May 5, 2021 was forgiven for the full amount of $
15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2022, and related notes included elsewhere in this filing. This discussion and analysis and other parts of this filing contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under “Risk Factors” and elsewhere in this filing. You should carefully read the “Risk Factors” section of this filing to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled “Cautionary Note Regarding Forward-Looking Statements” in this filing.
Overview
This overview and outlook provide a high-level discussion of our operating results and significant known trends that affect our business. We believe that an understanding of these trends is important to understanding our financial results for the periods being reported herein as well as our future financial performance. This summary is not intended to be exhaustive, nor is it intended to be a substitute for the detailed discussion and analysis provided elsewhere in this report.
About SeqLL
We are a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields. We leverage our expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute major advancements to scientific research and development.
Our customers are primarily the early adopters of genomics technology and tSMS in academic research, biomarker discovery, and molecular diagnostic product development.
Since our incorporation in 2014, we have devoted the majority of our efforts to technology development, business planning, and advancing research collaborations.
We incurred net losses of $925,949 and $639,499 for the three months ended September 30, 2022 and 2021, respectively, and net losses of $2,858,818 and $2,306,420 for the nine months ended September 30, 2022 and 2021 respectively. We had negative cash flow from operating activities of $2,913,571 and $1,022,971 for the nine months ended September 30, 2022 and 2021, respectively, and had an accumulated deficit of $17,272,669 as of September 30, 2022.
Results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond our control. Our business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. We cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact our business.
Our financial results have been, and will continue to be, impacted by several significant trends, which are described below. While these trends are important to understanding and evaluating our financial results, this discussion should be read in conjunction with our consolidated financial statements and the notes thereto within the Consolidated Financial Statements section of this report, and trends discussed in “Risk Factors” in Item 1-A of Part II of this report.
16
Results of Operations
Comparison of the Three Months Ended September 30, 2022 and 2021
The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021:
|
Three months ended
September 30, |
||||||||
| 2022 | 2021 | |||||||
| Revenue | ||||||||
| Sales | $ | - | $ | 15,937 | ||||
| Grant revenue | - | 34,964 | ||||||
| Total revenue | - | 50,901 | ||||||
| Cost of sales | - | 4,049 | ||||||
| Gross profit | - | 46,852 | ||||||
| Operating expenses | ||||||||
| Research and development | 428,771 | 90,658 | ||||||
| General and administrative | 489,729 | 360,944 | ||||||
| Total operating expenses | 918,500 | 451,602 | ||||||
| Operating loss | (918,500 | ) | (404,750 | ) | ||||
| Other (income) and expenses | ||||||||
| Unrealized loss on marketable securities | 242 | - | ||||||
| Interest income | (9,981 | ) | - | |||||
| Other income | - | (93 | ) | |||||
| Change in fair value of convertible notes | - | 193,776 | ||||||
| Interest expense | 17,188 | 41,066 | ||||||
| Net loss | $ | (925,949 | ) | $ | (639,499 | ) | ||
| Net loss per share - basic and diluted | $ | (0.08 | ) | $ | (0.09 | ) | ||
| Weighted average common shares - basic and diluted | 11,886,379 | 7,171,232 | ||||||
Revenues
Our revenues during the three months ended September 30, 2022 were $0 as compared to revenues of $50,901 during the three-month period ended September 30, 2021, representing a decrease of $50,901, or 100%. During the three months ended September 30, 2022, no revenue generating activities were performed, nor were any grants provided to us compared to revenue in the same period of 2021 with $15,937 of product sales and grants of $34,964. The decrease in revenue was due to the reduction in research services and business activities due to our relocation to Billerica, Massachusetts. This relocation, which was finalized in September 2022, resulted in our temporarily not having facilities that were sufficient to perform our research services and business activities. We expect to resume normal operations in the final quarter of 2022. In addition, there was no grant revenue during the three months ended September 30, 2022 due primarily to 2022 being the final year of the award.
Gross Profit
Gross profit for the three months ended September 30, 2022 was $0, as compared to gross profit of $46,852 for the three months ended September 30, 2021, due to the fact that we had no revenue in the three month period ended September 30, 2022.
Research and Development Expenses
Research and development expenses increased by $338,113, or 373%, from $90,658 for the three months ended September 30, 2021 to $428,771 for the three months ended September 30, 2022. The increase in expenses was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. We expect these expenditures to increase over the final quarter of 2022 and beyond as we increase our research and development efforts to pre-pandemic levels.
17
General and Administrative Expenses
General and administrative expenses increased by $128,785 or 36%, from $360,944 for the three months ended September 30, 2021 compared to $489,729 for the three months ended September 30, 2022. The increase was primarily attributable to increased operating expenses as a public company, including the addition of accounting, legal and audit related expenses as well as increased payroll expense of approximately $130,000. General and administrative expenditures will continue to increase during 2022 to support ongoing financial reporting and compliance activities.
Interest and Other Income/Loss
We recognized $9,981 of interest income in the three-month period ended September 30, 2022. No such income was noted for the three-month period ended September 30, 2021.
We recognized $193,776 related to the change in fair value of our convertible notes in the three-month period ended September 30, 2021. No such convertible notes were in existence for the three-month period ended September 30, 2022.
We recognized interest expense of $17,188 and $41,066 in the three months ended September 30, 2022 and 2021, respectively, representing a decrease of $23,878, or 58%. The decrease in interest expense was due to a decrease in our outstanding indebtedness as a result of the conversion of $2.1 million in notes to equity concurrently with the consummation of our initial public offering on August 31, 2021.
Net Loss
Overall, the net loss increased by $286,450, or 45%, to $925,949 as compared to $639,499 for the three months ended September 30, 2021. The increase in net loss was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic and our increase in general and administrative expenses that are related to being a public company.
Comparison of the Nine Months Ended September 30, 2022 and 2021
The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021:
|
Nine months ended
September 30, |
||||||||
| 2022 | 2021 | |||||||
| Revenue | ||||||||
| Sales | $ | 1,177 | $ | 48,021 | ||||
| Grant revenue | 77,482 | 127,009 | ||||||
| Total revenue | 78,659 | 175,030 | ||||||
| Cost of sales | 690 | 44,792 | ||||||
| Gross profit | 77,969 | 130,238 | ||||||
| Operating expenses | ||||||||
| Research and development | 1,129,286 | 133,074 | ||||||
| General and administrative | 1,700,340 | 1,173,565 | ||||||
| Total operating expenses | 2,829,626 | 1,306,639 | ||||||
| Operating loss | (2,751,657 | ) | (1,176,401 | ) | ||||
| Other (income) and expenses | ||||||||
| Unrealized loss (gain) on marketable securities | (54,266 | ) | - | |||||
| Realized loss on marketable securities | 106,324 | - | ||||||
| Interest income | (18,457 | ) | - | |||||
| Other income | - | (190,193 | ) | |||||
| Change in fair value of convertible notes | - | 195,962 | ||||||
| Loss on extinguishment of convertible notes | - | 934,257 | ||||||
| Interest expense | 73,560 | 189,993 | ||||||
| Net loss | $ | (2,858,818 | ) | $ | (2,306,420 | ) | ||
| Net loss per share - basic and diluted | $ | (0.24 | ) | $ | (0.41 | ) | ||
| Weighted average common shares - basic and diluted | 11,886,379 | 5,642,100 | ||||||
18
Revenues
Our revenues during the nine months ended September 30, 2022, were $78,659 as compared to revenues of $175,030 during the nine months ended September 30, 2021, representing a decrease of $96,371, or 55%. During the nine months ended September 30, 2022, revenue included grants of $77,482 and $1,777 of revenues from product sales, and no sales from research services as compared to revenue in the same period of 2021 from product sales of $31,537, grants of $127,009 and $16,484 in research services. The decrease in revenue was due to the reduction in research services and revenue generating activities due to our relocation to Billerica, Massachusetts. This relocation, which was finalized in September of 2022, resulted in our temporarily not having facilities that were sufficient to perform our research services and business activities. We expect to resume normal operations in the final quarter of 2022
Gross Profit
Gross profit for the nine months ended September 30, 2022 was $77,969, as compared to gross profit of $130,238 for the nine months ended September 30, 2021, which represented a decrease of $52,269, or 40%, primarily due to the fact that we had immaterial product and research services sales in 2022 due to our relocation to Billerica, Massachusetts as well as decreased grant revenue for the nine month period ended September 30, 2022.
Research and Development Expenses
Research and development expenses increased by $996,212, or 749%, from $133,074 for the nine months ended September 30, 2021 compared to $1,129,286 for the nine months ended September 30, 2022. The increase in expenses was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. We expect these expenditures to increase in the last quarter of 2022 and beyond as we increase our research and development efforts to pre-pandemic levels.
General and Administrative Expenses
General and administrative expenses increased by $526,775, or 45%, from $1,173,565 for the nine months ended September 30, 2021 compared to $1,700,340 for the nine months ended September 30, 2022. The increase was primarily attributable to increased operating expenses as a public company, including the addition of accounting, legal and audit related expenses as well as increased payroll expense of approximately $530,000. General and administrative expenditures will continue to increase during the remainder of 2022 to support ongoing financial reporting and compliance activities.
Interest and Other Income/Loss
We recognized $52,058 in net realized and unrealized losses on the marketable securities during the nine months ended September 30, 2022. We did not hold such investments during the nine months ended September 30, 2021.
We recognized $18,457 of interest income in the nine-month period ended September 30, 2022. No such income was noted for the nine-month period ended September 30, 2021.
In the nine-month period ended September 30, 2021, we recognized $190,193 from the receipt of funds in connection with the PPP pursuant to the CARES Act that was signed into law on March 27, 2020. No such receipt was noted for the nine-month period ended September 30, 2022.
We recognized $195,962 related to the change in fair value of our convertible notes in the nine months ended September 30, 2021. No such convertible notes were in existence for the nine months ended September 30, 2022.
We recognized a loss on extinguishment of debt totaling $934,257 in the nine-month period ended September 30, 2021 related to certain convertible notes. The loss on the extinguishment of debt represented the excess of the fair value of these convertible notes totaling $3,075,987 over their carrying value of $2,141,730 at their amendment date in the first quarter of 2021. We did not incur such losses during the nine months ended September 30, 2022.
We recognized interest expense of $73,560 and $189,993 in the nine months ended September 30, 2022 and 2021, respectively, representing a decrease of $116,433, or 61%. The decrease in interest expense was due to a decrease in our outstanding indebtedness as a result of the conversion of $2.1 million in notes to equity concurrently with the consummation of our initial public offering on August 31, 2021.
19
Net Loss
Overall, the net loss increased by $552,398, or 24%, to $2,858,818 as compared to $2,306,420 for the nine months ended September 30, 2021. This increase in net loss is primarily attributable to increased operating expenses as a public company and our progressive return to research and development activities to levels of pre-COVID-19 pandemic. This increase in operating expenses was offset by our loss on extinguishment of our convertible notes in the nine months ended September 30, 2021 in the amount of $934,257. No such loss occurred during the nine-month period ended September 30, 2022.
Liquidity and Capital Resources
The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Even though we experienced negative cash flows from operations of $2,913,571 for the nine months ended September 30, 2022, as a result of our recent common stock offering in August 2021, we had cash and cash equivalents of $4,453,521 and short-term investments in marketable securities of $2,499,685 at September 30, 2022.
As of September 30, 2022, we had $4,453,521 of cash and cash equivalents. Cash and cash equivalents increased $438,393 at September 30, 2022 as compared to December 31, 2021 due to the sale of approximately $5.9 million in our marketable securities, offset by the purchase of approximately $2.5 million of marketable securities, and cash spending for operating activities for the nine-month period ended September 30, 2022.
Since inception, we have funded our operations primarily through equity and debt financings, as well as from modest sales of products and research services. As of September 30, 2022, we had an accumulated deficit of $17,272,669.
In August 2021, we issued 3,060,000 shares of common stock to investors in our initial public offering. The gross proceeds from our initial public offering was $13.0 million. We incurred offering expenses of $1.6 million in cash. We also converted $2.1 million of debt into 641,895 shares of common stock at our initial public offering.
On September 29, 2021, we issued 189,000 shares of common stock to the underwriters at a price of $4.24 per share from the partial exercise of the overallotment option, increasing the net proceeds by approximately $730,000, net of offering costs.
We believe the net proceeds from our initial public offering, together with our cash generated from commercial sales and research activity, will enable us to fund our operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect.
Our future capital requirements will depend on many factors, including:
| ● | our ability to successfully further develop our technologies and create innovative products in our markets, including the costs associated with the development of our tSMS platform across multiple market segments, for which we have budgeted approximately $1 million in 2022 and $2 million in 2023 in support of our collaborative efforts in detection tools for heart disease and cancer, and chromatin mapping in genome biology; |
| ● | scientific progress in research and development of our collaborative programs, including the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights, as well as the costs associated with any product or technology that we may in-license or acquire; and |
| ● | the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; including the need to enter into other collaborations to enhance or complement our product and service offerings. |
We plan to continue seeking additional financing sources from time to time to meet our working capital requirements, make continued investment in research and development and make capital expenditures needed for us to maintain and expand our business. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, or if we expend capital on projects that are not successful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited. In addition, if we raise additional funds through further issuances of equity or debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock.
20
Cash Flows
The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented.
|
Nine Months Ended
September 30, |
||||||||
| 2022 | 2021 | |||||||
| Cash proceeds (used in) provided by: | ||||||||
| Operating activities | $ | (2,913,571 | ) | $ | (1,022,971 | ) | ||
| Investing activities | 3,351,964 | (5,250 | ) | |||||
| Financing activities | - | 12,334,906 | ||||||
| Net increase in cash and cash equivalents | $ | 438,393 | $ | 11,306,685 | ||||
Net cash used in operating activities
Net cash used in operating activities was approximately $2.9 million and $1.0 million for the nine months ended September 30, 2022 and 2021, respectively. The increase in operating spending was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. In addition, we experienced an increase in our general and administrative spending since we became a public company in August 2021.
We anticipate our research and development efforts and on-going general and administrative costs will generate negative cash flows from operating activities for the foreseeable future.
Net cash used in investing activities
Net cash provided by (used in) investing activities was approximately $3.3 million and immaterial for the nine months ended September 30, 2022 and 2021, respectively. The increase was primarily attributable to our sales of our entire portfolio of marketable securities during the first quarter of 2022, which is offset by our purchases of additional marketable securities in the third quarter of 2022.
Net cash provided by financing activities
Net cash provided by financing activities was $0 and approximately $12.3 million for the nine months ended September 30, 2022 and 2021, respectively. This increase is attributable to our initial public offering that occurred in August of 2021 and the related issuance of common stock, settlement of convertible notes, and payment of offering related expenses.
21
Recent Accounting Pronouncements
In August 2020, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We adopted this standard on January 1, 2022, which had no material impact to our condensed consolidated financial statements.
In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”) which establishes new accounting and disclosure requirements for leases. ASU No. 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. The Company adopted ASU 2016-02 in the first quarter of 2022 using the effective date approach to recognize and measure leases as of the adoption date. The Company has elected to utilize the available practical expedient to not separate lease components from non-lease components as well as the package of practical expedients that allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. At the date of adoption on January 1, 2022, this guidance had no impact to our condensed consolidated financial statements.
We do not believe that any other recently issued but not yet effective accounting pronouncements are expected to have a material effect on our consolidated financial statements.
Critical Accounting Policies and Estimates
We prepare our financial statements and accompanying notes in conformity with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions about future events that affect reported amounts. Estimations are considered critical accounting estimates based on, among other things, its impact on the portrayal of our financial condition, results of operations, or liquidity, as well as the degree of difficulty, subjectivity, and complexity in its deployment. Critical accounting estimates address accounting matters that are inherently uncertain due to unknown future resolution of such matters. Management routinely discusses the development, selection, and disclosure of each critical accounting estimates.
Other than those noted within Note 2 to our unaudited consolidated financial statements, there have been no significant changes to our critical accounting policies and estimates during the three-and nine-month periods ended September 30, 2022 as compared to the information contained in our 2021 Form 10-K filed with the SEC. Reference should be made to the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 for a full description of other significant accounting policies.
22
JOBS Act
Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
For as long as we remain an emerging growth company under the recently-enacted JOBS Act, we will, among other things:
| ● | be permitted to have only two years of audited financial statements and only two years of related selected financial data and management’s discussion and analysis of financial condition and results of operations disclosure; |
| ● | be entitled to rely on an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; |
| ● | be entitled to reduced disclosure obligations about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and |
| ● | be exempt from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements. |
We currently intend to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an “emerging growth company.” Among other things, this means that our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an emerging growth company, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected.
Likewise, so long as we qualify as an emerging growth company, we may elect not to provide certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. As a result, investor confidence in our company and the market price of our common stock may be materially and adversely affected.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Not required under Regulation S-K for smaller reporting companies.
Item 4. Controls and Procedures.
Evaluation of disclosure controls and procedures
Our Chief Executive Officer (who is our principal executive officer) and Chief Financial Officer (who is our principal financial officer), conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) as of September 30, 2022. As of September 30, 2022, based upon the evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective. Disclosure controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the nine months ended September 30, 2022 that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our disclosure controls and procedures and internal control over financial reporting are designed to reasonably ensure that designed control objectives are achieved. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.
23
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None
Item 1A. Risk Factors
There have been no material changes to the risk factors set forth in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 23, 2022 ( our “Annual Report”) or our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 filed with the SEC on May 12, 2022 and August 12, 2022, respectively (collectively, our “Quarterly Reports”).
Our business involves significant risks. You should carefully consider the risks and uncertainties described in our Annual Report and our Quarterly Reports, together with all of the other information in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as included in our Annual Report. The risks and uncertainties described in our Annual Report, our Quarterly Reports and this report are not the only ones we face. Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price of our common stock could decline and you could lose part or all of your investment.
Item 2. Unregistered Securities Sales of Equity Securities and Use of Proceeds
Sales of Unregistered Securities
There have been no sales of unregistered securities within the period covered by this report that would be required to be disclosed pursuant to Item 701 of Regulation S-K.
Repurchases of Shares or of Company Equity Securities
None.
Item 3. Default Upon Senior Securities
None
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information
None.
24
Item 6. Exhibits
The following documents are filed as a part of this report or incorporated herein by reference:
25
SIGNATURES
Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SEQLL INC. | ||
| Date: November 8, 2022 | /s/ Daniel Jones | |
| Daniel Jones | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: November 8, 2022 | /s/ Frances Scally | |
| Frances Scally | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
26